Results 141 to 150 of about 49,882 (187)
Some of the next articles are maybe not open access.
Current Problems in Pediatric and Adolescent Health Care, 2002
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +2 more sources
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +2 more sources
Simplified method for the discrimination of acute myelogenous and non-myelogenous leukemias
Blut, 1983Rapid discrimination of acute myelogenous and non-myelogenous leukemias is of great importance when chemotherapy is urgently needed in severely ill patients. For decades the most reliable cytochemical method for this classification is the demonstration of myeloperoxidase in blast cells [1-4, 6, 7].
F W, Hirsch, R, Engelhardt, G W, Löhr
openaire +2 more sources
Therapy of Acute Myelogenous Leukemia
Blood Reviews, 1983Over the past 10 years, there have been substantial advances in the treatment of AML. Intensive induction chemotherapy using 7-day courses of cytarabine and daunorubicin or amsacrine produce remission in 60% to 85% of patients. Median remission duration is 9 to 16 months. In some series, 20% to 40% of patients are in continuous remission for 2 years or
K A, Foon, R P, Gale
openaire +3 more sources
Current Opinion in Oncology, 2003
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Clinical Journal of Oncology Nursing, 2005
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Cancer, 1978
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
MYELOGENOUS AND LYMPHATIC LEUKEMIA
AJN, American Journal of Nursing, 1919I have been asked to tell something about my work with blood diseases. I have chosen as my subject, "Leukemia," as I feel that as nurses we come in contact with this terrible disease less often than any other, and have, therefore, considered it a rare condition. Review of the literature.-It has been stated that in 1845, Huges Bennett recorded a case of
openaire +1 more source
Biotherapy of chronic myelogenous leukemia
Annals of Hematology, 1995The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML.
W E, Aulitzky +3 more
openaire +2 more sources
Immunotherapy for acute myelogenous leukemia
Irish Journal of Medical Science, 1974One hundred and seven untreated patients with acute myelogenous leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October 1970 and 31 January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment-a group to receive chemotherapy alone and a group to ...
openaire +3 more sources
Acute myelogenous leukemia heteroantisera
Clinical Immunology and Immunopathology, 1980Abstract Antisera were raised in New Zealand white rabbits to acute myelogenous leukemia (AML) cells. Reactivity of the antisera against normal T lymphocytes was eliminated by pretreating the rabbits with anti-leukocyte serum (ALS) and precoating the immunizing cell with ALS.
R, Billing +4 more
openaire +2 more sources